Merganser was founded by experienced biotech executives and develops novel therapies for orphan diseases. We operate a virtual project based model and take projects from preclinical to clinical proof of concept. Careful project selection ensures that our projects are attractive to big pharma or big biotech partners. We are currently working on novel hepcidin mimetic peptides for the treatment of rare hematological diseases.